Phase I-II study of pixantrone, etoposide, bendamustine and rituximab in patients with relapsed aggressive B -or T-cell non-Hodgkin lymphoma

Project summary

Treatment options for patients with non-Hodgkin’s lymphoma that has recurred are minimal. The chance of survival is less than a year. That is why effective treatment for this group of patients is desperately needed.
The researchers think that a certain combination treatment (PREBEN) can be interesting. This consists of various medicines: chemotherapy and immunotherapy (rituximab).
This study will show whether the chance of survival of non-Hodgkin patients for whom previous treatment has failed increases with the addition of immunotherapy. If this is the case more patients will probably also be eligible for a stem cell transplant. This also contributes to better chances of survival.

With this research the researchers want to improve the chance of survival of patients with a non-Hodgkin’s lymphoma for whom previous treatment has failed.